MS4A1 and Immunodeficiency: Although it is important to consider that a possible complication of current anti-CD20 therapy could be immunodeficiency and/or immunopathologies, we provide evidence for the combined use of LRAs and anti-CD20 therapies for the depletion of viral-reactivated cells in patients on ART.